Skip to main content

Table 5 DNA Methyltransferase inhibitors in clinical trials

From: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Study Agents

Other agents

Disease

Dosage

Clinical trails

No Pts

Response

Reference

decitabine

GO

Elderly, untreated AML

20 mg/m2 IV ×5d, GO 3 mg/m2 IV × 1 d 5

Phase II

33

CR/CRp: 42%

[39]

decitabine

GO

Relapsed and refractory AML

20 mg/m2 IV ×5d

retrospective

79

CR/CRp: 21%

[40]

Azacytidine

 

Elderly relapsed and refractory AML

75 mg/m2/d IV, d1-7

retrospective

184

CR/CRi: 10%

[41]

Azacytidine

gemtuzumab ozogamicin (GO)

high-risk AML

75 mg/m2/d IV, d1-7

retrospective

56

CR/CRi: 10%

[42]

Azacytidine

Bortezomib

Relapsed and refractory AML

75 mg/m2/d IV, d1-7

Phase I

23

CR/CRi: 21%

[43]

  1. Abbreviations: GO: gemtuzumab ozogamycin; CR: complete remission; CRi: CR with incomplete count recovery; CRp: CR without platelet recovery; MTD: maximal tolerated dose;